Matilde Saggese

4.0k total citations
25 papers, 804 citations indexed

About

Matilde Saggese is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Matilde Saggese has authored 25 papers receiving a total of 804 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Matilde Saggese's work include Lung Cancer Treatments and Mutations (14 papers), HER2/EGFR in Cancer Research (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Matilde Saggese is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), HER2/EGFR in Cancer Research (8 papers) and Colorectal Cancer Treatments and Studies (7 papers). Matilde Saggese collaborates with scholars based in United Kingdom, United States and Japan. Matilde Saggese's co-authors include Licia Selleri, Andrea Brendolan, Suresh S. Ramalingam, Xiaojing Ma, Jianguo Liu, Yoichiro Homma, Elaine Y. Chung, Yunhua Zhang, Jihong Han and Roy L. Silverstein and has published in prestigious journals such as Journal of Clinical Oncology, Immunity and Cancer Research.

In The Last Decade

Matilde Saggese

23 papers receiving 794 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matilde Saggese United Kingdom 14 389 377 260 168 137 25 804
Zhengwei Dong China 17 341 0.9× 405 1.1× 213 0.8× 78 0.5× 278 2.0× 39 785
C. Mascaux Belgium 12 375 1.0× 266 0.7× 225 0.9× 86 0.5× 101 0.7× 22 704
Kailun Fei China 14 481 1.2× 265 0.7× 184 0.7× 187 1.1× 101 0.7× 23 706
Futoshi Miyazono Japan 17 386 1.0× 367 1.0× 166 0.6× 181 1.1× 140 1.0× 33 827
Shannon Zhang United States 12 258 0.7× 220 0.6× 178 0.7× 225 1.3× 82 0.6× 20 575
Khalil Choucair United States 12 234 0.6× 178 0.5× 337 1.3× 108 0.6× 124 0.9× 36 693
Xinxin Zhu China 13 387 1.0× 144 0.4× 157 0.6× 242 1.4× 111 0.8× 19 650
Mu-Kuan Chen Taiwan 16 316 0.8× 125 0.3× 392 1.5× 130 0.8× 235 1.7× 24 825
Minish Jain United States 14 459 1.2× 155 0.4× 258 1.0× 275 1.6× 74 0.5× 68 828
Stephanie Sitterding United States 8 200 0.5× 315 0.8× 162 0.6× 313 1.9× 78 0.6× 10 771

Countries citing papers authored by Matilde Saggese

Since Specialization
Citations

This map shows the geographic impact of Matilde Saggese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matilde Saggese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matilde Saggese more than expected).

Fields of papers citing papers by Matilde Saggese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matilde Saggese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matilde Saggese. The network helps show where Matilde Saggese may publish in the future.

Co-authorship network of co-authors of Matilde Saggese

This figure shows the co-authorship network connecting the top 25 collaborators of Matilde Saggese. A scholar is included among the top collaborators of Matilde Saggese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matilde Saggese. Matilde Saggese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Ying, Yong He, Wěi Li, et al.. (2021). Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted Oncology. 16(2). 165–176. 90 indexed citations
2.
Lü, Shun, Ignacio Casarini, Terufumi Kato, et al.. (2021). Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer. 22(4). 371–375. 43 indexed citations
3.
4.
5.
6.
Brown, Helen, Johan Vansteenkiste, Kazuhiko Nakagawa, et al.. (2019). Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. Journal of Thoracic Oncology. 15(1). 138–143. 38 indexed citations
7.
Macpherson, Iain R., Pavlina Spiliopoulou, Saeed Rafii, et al.. (2019). A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research. 22(1). 1–1. 48 indexed citations
8.
Brown, Heather A., Johan Vansteenkiste, Kazuhiko Nakagawa, et al.. (2018). MA15.03 PD-L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR-TKIs in the FLAURA Trial. Journal of Thoracic Oncology. 13(10). S408–S408. 3 indexed citations
9.
Zhou, Chao, Ying Cheng, Yong He, et al.. (2018). P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S507–S508. 3 indexed citations
10.
Cho, Byoung Chul, Ki Hyeong Lee, Arunee Dechaphunkul, et al.. (2018). Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of Thoracic Oncology. 14(1). 99–106. 93 indexed citations
11.
12.
Rodríguez‐Vida, Alejo, Matilde Saggese, Simon Hughes, et al.. (2015). Complexity of FGFR signalling in metastatic urothelial cancer. Journal of Hematology & Oncology. 8(1). 119–119. 23 indexed citations
13.
Lemech, Charlotte, et al.. (2014). Patients' Perceptions of Research Biopsies in Phase I Oncology Trials. Oncology. 88(2). 95–102. 13 indexed citations
14.
Arkenau, Hendrik‐Tobias, Matilde Saggese, Antoine Hollebecque, et al.. (2014). A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.. Journal of Clinical Oncology. 32(15_suppl). 2620–2620. 16 indexed citations
15.
Saggese, Matilde, et al.. (2013). Research biopsies in the context of early phase oncology studies: clinical and ethical considerations. Oncology Reviews. 7(1). 5–5. 14 indexed citations
16.
17.
Koss, Matthew, Alexandre Bolze, Andrea Brendolan, et al.. (2012). Congenital Asplenia in Mice and Humans with Mutations in a Pbx/Nkx2-5/p15 Module. Developmental Cell. 22(5). 913–926. 52 indexed citations
18.
Costanzo, Francesco Di, et al.. (2008). Bevacizumab in Non-Small Cell Lung Cancer. Drugs. 68(6). 737–746. 35 indexed citations
19.
Chung, Elaine Y., Jianguo Liu, Yoichiro Homma, et al.. (2007). Interleukin-10 Expression in Macrophages during Phagocytosis of Apoptotic Cells Is Mediated by Homeodomain Proteins Pbx1 and Prep-1. Immunity. 27(6). 952–964. 196 indexed citations
20.
Poznak, Catherine Van, Simon S. Cross, Matilde Saggese, et al.. (2006). Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours. Journal of Clinical Pathology. 59(1). 56–63. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengwei Dong Breakdown of academic impact, for papers by C. Mascaux Breakdown of academic impact, for papers by Kailun Fei Breakdown of academic impact, for papers by Futoshi Miyazono Breakdown of academic impact, for papers by Shannon Zhang Breakdown of academic impact, for papers by Khalil Choucair Breakdown of academic impact, for papers by Xinxin Zhu Breakdown of academic impact, for papers by Mu-Kuan Chen Breakdown of academic impact, for papers by Minish Jain Breakdown of academic impact, for papers by Stephanie Sitterding
Rankless by CCL
2026